VBI VACCINES INC. (TSE:VBV) Files An 8-K Other EventsItem 8.01 Other Events.
On August 15, 2017, VBI Vaccines Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug Application for VBI-1901 targeting glioblastoma multiforme. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated August 15, 2017 |
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme VBI-1901 is a novel immunotherapy developed using VBI’s eVLP technology On track to initiate a Phase I/2a clinical study in the second half of 2017 CAMBRIDGE,…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
